109 related articles for article (PubMed ID: 37661348)
1. Curcumin potentiates the ErbB receptors inhibitor Afatinib for enhanced antitumor activity in malignant mesothelioma.
Benvenuto M; Nardozi D; Palumbo C; Focaccetti C; Carrano R; Angiolini V; Cifaldi L; Lucarini V; Mancini P; Kërpi B; Currenti W; Bei R; Masuelli L
Int J Food Sci Nutr; 2023 Nov; 74(7):746-759. PubMed ID: 37661348
[TBL] [Abstract][Full Text] [Related]
2. Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line.
Masuelli L; Benvenuto M; Di Stefano E; Mattera R; Fantini M; De Feudis G; De Smaele E; Tresoldi I; Giganti MG; Modesti A; Bei R
Oncotarget; 2017 May; 8(21):34405-34422. PubMed ID: 28159921
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.
Bei R; Benvenuto M; Focaccetti C; Fazi S; Moretti M; Nardozi D; Angiolini V; Ciuffa S; Cifaldi L; Carrano R; Palumbo C; Miele MT; Bei R; Barillari G; Manzari V; De Smaele E; Modesti A; Masuelli L
J Transl Med; 2022 Jun; 20(1):286. PubMed ID: 35752861
[TBL] [Abstract][Full Text] [Related]
4. Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.
Chen J; Liu J; Xu B; Cao Y; Liang X; Wu F; Shen X; Ma X; Liu J
Toxicol Appl Pharmacol; 2022 Mar; 438():115911. PubMed ID: 35143806
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
7. Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.
Agatsuma N; Yasuda Y; Ozasa H
J Thorac Oncol; 2017 Sep; 12(9):e141-e143. PubMed ID: 28838714
[No Abstract] [Full Text] [Related]
8. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.
Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M
Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644
[TBL] [Abstract][Full Text] [Related]
9. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
Masuelli L; Benvenuto M; Fantini M; Marzocchella L; Sacchetti P; Di Stefano E; Tresoldi I; Izzi V; Bernardini R; Palumbo C; Mattei M; Lista F; Galvano F; Modesti A; Bei R
J Biol Regul Homeost Agents; 2013; 27(1):105-19. PubMed ID: 23489691
[TBL] [Abstract][Full Text] [Related]
10. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
[TBL] [Abstract][Full Text] [Related]
12. Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis.
Di Meo F; Filosa S; Madonna M; Giello G; Di Pardo A; Maglione V; Baldi A; Crispi S
J Exp Clin Cancer Res; 2019 Aug; 38(1):360. PubMed ID: 31419989
[TBL] [Abstract][Full Text] [Related]
13. Afatinib is active in osteosarcoma in osteosarcoma cell lines.
Cruz-Ramos M; Zamudio-Cuevas Y; Medina-Luna D; Martínez-Flores K; Martínez-Nava G; Fernández-Torres J; López-Reyes A; Solca F
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1693-1700. PubMed ID: 32333142
[TBL] [Abstract][Full Text] [Related]
14. Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.
Zhang C; Hao Y; Wu L; Dong X; Jiang N; Cong B; Liu J; Zhang W; Tang D; De Perrot M; Zhao X
Int J Oncol; 2018 Dec; 53(6):2531-2541. PubMed ID: 30272283
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
[TBL] [Abstract][Full Text] [Related]
16. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
[TBL] [Abstract][Full Text] [Related]
17. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways.
Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P
Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044
[TBL] [Abstract][Full Text] [Related]
18. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma.
Noguchi S; Yasumura M
Vet Res Commun; 2023 Dec; 47(4):2207-2213. PubMed ID: 36991174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
